Stock Analysis, Dividends, Split History

ITUS / ITUS Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.64
Volume69,800.00
Market Cap ($M)61.44
Enterprise Value ($M)57.22
Book Value ($M)6.33
Book Value / Share0.34
Price / Book10.13
NCAV ($M)5.72
NCAV / Share0.31
Price / NCAV15.17
Share Statistics
Common Stock Shares Outstanding 16,602,759
Common Shares Outstanding 16,609,399
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.63
Return on Assets (ROA)-0.89
Return on Equity (ROE)-5.07
Balance Sheet (mrq) ($M)
Assets7.29
Liabilities0.00
Quick Ration/a
Current Ratio5.06
Income Statement (mra) ($M)
Revenues362,500.00
Operating Income-6.08
Net Income-5.01
Earnings Per Share Basic And Diluted-0.58
Earnings Per Share Basic-0.58
Earnings Per Share Diluted-0.58
Cash Flow Statement (mra) ($M)
Cash From Operations-3.80
Cash from Investing-2.74
Cash from Financing-2.74
Identifiers and Descriptors
CUSIP45069V203
Central Index Key (CIK)715446
Related CUSIPS
45069V104

Split History

Stock splits are used by ITUS Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Anixa Biosciences Could Rock The Foundation Of The Cancer Diagnostics Industry

2018-10-05 seekingalpha
Cchek, ANIX's diagnostic platform, could accurately screen for all cancers using a liquid biopsy, flow cytometry and AI. (13-3)

ParkerVision Announces Changes to Board of Directors

2018-09-20 accesswire
JACKSONVILLE, FL / ACCESSWIRE / September 20, 2018 / ParkerVision, Inc. (OTCQB: PRKR), announced today that it has reduced the size of its Board of Directors from eight to five members. In connection with the restructuring, the Board accepted the resignation of four directors: Mr. William Hightower, Mr. John Metcalf, Dr. Nam Suh and Mr. Papken der Torossian. The Company had no disagreements with any of its parting directors.

CUSIP: 45069V203